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Dendrimer‑based drug delivery systems:
history, challenges, and latest developments
Juan Wang1*, Boxuan Li2, Li Qiu1, Xin Qiao1 and Hu Yang3

Abstract
Since the first dendrimer was reported in 1978 by Fritz Vögtle, dendrimer research has grown exponentially, from synthesis to application in the past four decades. The distinct structure characteristics of dendrimers include nanoscopic
size, multi-functionalized surface, high branching, cavernous interior, and so on, making dendrimers themselves ideal
drug delivery vehicles. This mini review article provides a brief overview of dendrimer’s history and properties and the
latest developments of dendrimers as drug delivery systems. This review focuses on the latest progress in the applications of dendrimers as drug and gene carriers, including 1) active drug release strategies to dissociate drug/gene from
dendrimer in response to stimuli; 2) size-adaptive and charge reversal dendrimer delivery systems that can better take
advantage of the size and surface properties of dendrimer; 3) bulk and micro/nano dendrimer gel delivery systems.
The recent advances in dendrimer formulations may lead to the generation of new drug and gene products and
enable the development of novel combination therapies.
Keywords: Dendrimer, Drug delivery, Dendrimer hydrogel, Microgel, Nanogel
Introduction
Dendrimer: a brief history and its unique properties

The word “dendrimer” derives from a Greek phrase of
“dendron”, which means tree or meros or branch [1]. As
early as 1978, Buhleir and coworkers synthesized and
reported the first “cascade” and “nonskid-chain-like”
molecules with molecular cavity topologies, which later
were recognized as the early forms of dendritic polymers
[2]. From 1979 to 1985, Donald A. Tomalia and his coworkers at the Dow Laboratories made a breakthrough
in the development of dendrimers [3]. They produced
polymers with a central, hollow core and tendrils that
branched outward, one from another, in a precise, predictable manner, which Tomalia called dendrimers [4].
These two scientific groups contributed to the early history of dendrimers. Up to now, more than 100 dendritic
*Correspondence: wangjuan@iccas.ac.cn
1
College of Biomedical Engineering, Sichuan University, Chengdu 610065,
Sichuan, China
Full list of author information is available at the end of the article

structures have been reported, in which polyamidoamine
(PAMAM) dendrimers, polypropyleneimine (PPI) dendrimers, as well as polyamide-, polyether-, polyester-,
and phosphorus-based dendrimers are some of the most
commonly recognized dendritic families [2, 3, 5–15]
(Table 1). Furthermore, thanks to the development of
various synthetic strategies, including efficient orthogonal click chemistry and multicomponent reaction (MCR),
many new dendrimers with the efficient synthetic process and structure diversity have emerged [16–19]. All
the development has promoted the flourishing of dendrimers and their applications in chemistry, materials,
and biological and medical science.
Dendrimer is different from traditional linear polymers by its mono-dispersity, high symmetricity, and surface polyvalency [20, 21]. The repeated growth reactions
during dendrimer synthesis lead to higher generation
and degree of branching, eventually forming a threedimensional spherical structure [20]. The distinct synthetic process makes dendrimer possess a well-defined
core–shell architecture and narrow polydispersity [1, 9].
The size, surface charge, peripheral functional groups,
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Table 1 Several commonly recognized dendrimers
Dendrimer Type

Cascade

PAMAM

PPI

Polylysine

Polyester

Phosphorus

First Reported

Vögtle et al. in
1978 [2]

Tomalia et al. in
1985 [3]

Meijer et al. in 1993
[12]

Denkewalter et al.
in 1981 [13]

Frechet et al. in
2002 [14]

Majoral et al. in 1994
[15]

Typical Chemical
Structure

and solubility of dendrimer could also be controlled by
the synthetic process [1]. For instance, higher-generation
dendrimers possess bigger size, larger interior cavity, and
more terminal functional groups. In addition to the routine analytical methods, including nuclear magnetic resonance (NMR), gel permeation chromatography (GPC),
dynamic light scattering (DLS), high-performance liquid
chromatography (HPLC), etc., characterization including
electrophoretic and mass spectroscopy measurements
have been developed to detect the mono-dispersity features and the effective charge of dendrimers [22, 23]. By
using capillary electrophoresis, the purity, electrophoretic mobility, and molecular charge distribution of various surface-charged PAMAM dendrimer nanoparticles
can be assessed [22]. The nanoscopic characteristics of

individual PAMAM dendrimers from generations 5 to
10 (G5 to G10) were confirmed by transmission electron
microscopy (TEM) reported by Jackson and coworkers
in 1998 [24]. The mean diameters increase from 4.3 nm
for PAMAM G5 to 14.7 nm for PAMAM G10. Besides
the nanoscopic feature, the multivalency of dendrimers
makes them amenable to further modification or conjugation with chemical species such as fluorophores, targeting ligands, drugs, and genes (Fig. 1).
Dendrimers as drug delivery vehicles

Dendrimers have emerged as an important group of
nanostructured carriers for the development of nanomedicine to treat various diseases. Because of structural
diversity and adaptability, dendrimers have been used to

Fig. 1 Structure diversity, adaptability and flexible cargo loading capacity of dendrimers. G1, G2, and G3 represent generation 1, 2, and 3,
respectively
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deliver drugs and genes in many different ways (Fig. 1).
For instance, dendrimers with a hydrophobic core and
a hydrophilic periphery may behave like unimolecular
micelles, and they have been utilized to solubilize hydrophobic drugs by entrapping them in the intramolecular
cavity [25, 26]. Cationic dendrimers have been extensively applied as non-viral gene carriers [27]. Dendrimer
surface groups can be conjugated with drugs and other
functional moieties (Fig. 2a) [28, 29]. Conjugating dendrimers with polymers such as polyethylene glycol
(PEG), polysaccharide, and polypeptide mainly enhances
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stability and solubility of the therapeutics to be delivered
[30]. PEGylation of dendrimers is a common process
through which PEG chains are conjugated to dendrimers, forming a unimolecular micelle [31]. Dendrimerpolysaccharide conjugates are usually adopted to endow
the nanomaterials with attractive binding properties and
improved compatibility [30, 32, 33]. Polysaccharides, for
instance chitosan, hyaluronic acid, cyclodextrin, and dextran have been broadly conjugated to dendrimers [34–
37]. A hyaluronic acid conjugated PAMAM dendrimer
showed enhanced tumor penetration property due to

Fig. 2 Ways to utilize dendrimers to deliver drugs and genes: a dendrimer conjugates and cleavable linkers used to make dendrimer conjugates, b
three drug/dendrimer encapsulation models, c dendrimer/gene complexation, and how cationic dendrimer helps enhance transfection efficiency

Wang et al. Journal of Biological Engineering

(2022) 16:18

the strong affinity of hyaluronic acid to CD44 receptors, which are overexpressed on tumor cells and cancer
stem cells [35]. He et al. reported a mannose conjugated
PAMAM dendrimer for the targeted delivery of liver-xreceptor (LXR) ligands to macrophages as mannose can
bind specifically to mannose reporter expressed on macrophage surface [38].
Dendrimer‑drug conjugates

Dendrimer-drug conjugates could reduce systemic
effects and increase efficacy at the targeted site compared with free drugs [25, 39]. It is reported that the
half-life of drugs can be increased by conjugating with
dendrimers. For instance, the half-life of methotrexate is increased to 24 h from 24 min when conjugated
with PAMAM dendrimer [29]. The extended circulating half-life can thus enhance the drug efficacy and
lower the frequency of drug administration, improving patient compliance. Solubility of drugs is enhanced
when conjugated with dendrimers. For example, paclitaxel’s water solubility is enhanced by 9000-fold when
conjugated with PAMAM dendrimer [29]. We previously reported a dendrimer-drug conjugate of DenTimol
and studied its therapeutic efficacy for glaucoma treatment [40]. An antiglaucoma drug precursor, (S)-4-[4(oxiranylmethoxy)-1,2,5-thiadiazol-3-yl]morpholine
(OTM), was conjugated to PAMAM dendrimer surface
through a PEG spacer. DenTimol is efficient at crossing
the cornea due to the good mucoadhesive property of
dendrimer, and about 8% of the dendrimer-drug permeated through the cornea in 4 h. DenTimol demonstrated
a stronger intraocular pressure (IOP) lowering effect
than timolol maleate in normotensive adult Brown Norway male rats. A single dose of DenTimol (10 μL of 0.5%
w/v timolol) resulted in an IOP reduction by an average
of 7.3 mmHg in less than 0.5 h, which was significantly
stronger than timolol PBS eye drops.
According to the United Food and Drug Association
(FDA), dendrimer-drug conjugates may be classified
into new drugs or combinational devices [41]. If drugs
can be cleaved from dendrimer-drug conjugates and
maintain their initial structure, this bureaucratic regulation issue could be avoided. Therefore, it is important
to examine the release of drugs from dendrimer-drug
conjugates (Fig. 2a) [28]. The most facile way is to conjugate drug to dendrimer via a cleavable or stimuli-liable
bond. Disulfide and thioketal linkers can be cleaved by
glutathione and reactive oxygen species (ROS) in tumor
cells, respectively. Therefore, they have been broadly used
in designing cleavable dendrimer-drug conjugates [42–
45]. pH-responsible linkers, especially acid-liable bonds
(e.g., acetal bond), are also used to make dendrimerdrug conjugates for cancer therapy due to the acidic
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tumor microenvironment [46]. We have constructed a
dendrimer-camptothecin-based hydrogel drug delivery
system [47]. In this novel drug delivery system, a pHcontrolled self-cleaving release of camptothecin (CPT) is
realized via the ammonolysis of ester bonds between the
dendrimer and CPT. The controlled self-cleaving release
mechanism significantly prolonged CPT release and thus
enhanced tumor inhibition.
Drug/dendrimer encapsulation

It is broadly recognized that the interior hydrophobic
cavities of dendrimers can accommodate hydrophobic
drugs (Fig. 2b) [25]. The encapsulation of hydrophobic
drugs in dendrimer cavities leads to an increase in water
solubility of the hydrophobic drugs [48]. This guest–
host encapsulation of drug/dendrimer makes dendrimer
behave as “unimolecular micelle” or “dendritic box” [25].
Low-generation dendrimers have limited drug loading capacity due to a small inner space. PEGylated dendrimers possess enhanced drug loading capacity because
of the agglomeration of PEGylated dendrimer molecules [31]. PEGylated dendrimers could also promote
enhanced permeation and retention effect (EPR) of the
encapsulated drugs [25].
Dendrimer/gene complexation

Amine-terminated PAMAM dendrimers have been
broadly used as gene transfection vectors (Fig. 2c)
[49–51]. Compared with branched polyethylenimine
(PEI), PAMAM dendrimers show higher biocompatibility and larger nucleic acid loading capacity [52]. The
nanoscopic size, spheroidal shape, and cationic surface
of PAMAM dendrimers facilitate cellular uptake of the
complexed nucleic acids [53]. In addition, the proton
sponge effect of PAMAM dendrimers helps endosomal
escape, which is a critical step for augmenting transfection efficiency [54]. We synthesized G4-FA and tested it
as a vector for local delivery of siRNA against vascular
endothelial growth factor A (siVEGFA) in a xenograft
tumor mouse model of head and neck squamous cell
carcinomas [55]. G4-FA facilitated the siVEGFA delivery, promoted its tumor-specific uptake, and substantially inhibited tumor growth of head and neck cancer.
Compared with siVEGFA group, two doses of G4-FA/
siVEGFA intratumorally administered eight days apart
resulted in a significant inhibition on tumor growth,
accompanied with profound reduction in angiogenesis.
Dendrimers are often decorated with additional functional moieties such as peptides to overcome intracellular gene delivery barriers [56]. Our group recently
reported PAMAM dendrimer complexed with a synthetic diblock nuclear-localization sequence peptide
(NLS) and used it for gene delivery [57]. The complexed
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NLS promoted the nuclear translocation of the entire
dendrimer/nucleic acid polyplex and then destabilized
the association between PAMAM and plasmid in the
nucleus, eventually leading to enhanced gene transfection. Similar to gene transfection, cationic dendrimers
are also able to bind with other negatively charged molecules, such as heparin or polyanions [58]. For instance,
the complex of polylysine dendrimer with heparin has
the potential to be used as stable anti-angiogenic therapeutics as it neutralizes the anticoagulant activity of
heparin in plasma [58].

Challenges and solutions to dendrimer‑based drug
and gene delivery
Challenges

Despite the benefits of dendrimers as drug delivery carriers, some challenges remain to be solved. The size and
surface chemistry of dendrimers are closely related to
their toxicity and biodistribution [59]. Size limitation is a
primary concern. PAMAM dendrimers of generation 5 or
lower can be sufficiently eliminated via glomerular filtration in the renal excretion pathway, while the clearance of
PAMAM generation 6 and higher rely more on the hepatic
clearance pathway [51, 60]. Dendrimers with sizes ranging
from 4–10 nm have the ability to interact with nanometric cellular components and have the capacity to overcome the cellular endocytosis barrier [59, 61]. However,
PAMAM dendrimers of generation 6 and higher have high
costs and severe toxicity [51], therefore the higher generation of PAMAM dendrimers are rarely used. Cationic dendrimers possess high binding capacity with nuclei or anion
compounds and facilitate cell internalization [62, 63].
However, cationic dendrimers often encounter nonspecific
adsorptions of plasma proteins and accelerated elimination by the reticuloendothelial system [59]. In addition, the
intracellular dissociation of dendrimers with nuclei acids is
limited [64]. Since the interaction of cationic dendrimers
with negatively charged cell membranes can result in the
destabilization of biological membrane and thus cause cell
lysis, cationic dendrimers generally exhibit higher toxicity,
especially at high doses, than neutral or anionic dendrimers [65–67]. Pryor et al. studied the toxicity of PAMAM
on embryonic zebrafish models and found that cationic
PAMAM generation 6 was statistically more toxic than
both neutral PAMAM generation 6 and anionic PAMAM
generation 6 at the same concentration [68]. Recent developments that have been made to address the challenges
mentioned above are summarized below.
Size adaptive dendrimer clustered nanoparticles

Strategies have been developed to use dendrimers as
building blocks to form larger nanoparticles. For instance,
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size-switchable or adaptive nanoparticles obtained from
dendrimer clusters have attractive features [69, 70]. They
are mostly hundreds of nanometers in size and remain
stable during blood circulation. After reaching the target tissues, nanoparticles would disintegrate and release
individual dendrimers to exert their extraordinary tissue
penetration and cell internalization property. Gao et al.
constructed size- and charge-adaptive clustered nanoparticles based on the electrostatic interaction between
PAMAM and 2,3-dimethyl maleic anhydride modified
poly(ethylene glycol)-block-polylysine (PEG-b-PLys) [69].
The clustered nanoparticle consists of PEG chains as the
outer layer and complexes of PLy chains with PAMAM as
the inner core. The clustered nanoparticles were shown
to have longer blood circulation when they were slightly
larger than 100 nm (112 nm) and had a slightly negatively
charged surface (-2.2 mV) with peripheral PEG chains.
Upon arriving at the infected lung tissue, carboxyl groups
in the PLy segments switched to amine groups in the
acidic microenvironment, disassembling dendrimer and
PEG-b-PLys. By taking advantage of small size (6.5 nm)
and positive charge (23.8 mV), the released PAMAM
dendrimers achieved effective penetration and long-term
retention inside biofilms.
Wang et al. fabricated size-switchable nanoparticles
through self-assembly of linear-dendritic triblock copolymer poly(ethylene glycol)-b-poly(ε-caprolac-tone)polyamidoamine (PEG-b-PCL-PAMAM) [70]. A singlet
oxygen responsive thioketal linker connected PEG-bPCL and PAMAM segments. The formed nanoparticles
had a hydrodynamic size of 118 nm and were shown to
accumulate in the tumor through the EPR effect. In the
blood vessel extravasation site, irradiation of 660 nm was
applied to generate singlet oxygens by the pre-loaded
photosensitizer chlorin e6 (Ce6). The produced singlet
oxygen not only killed cancer cells but also triggered the
cleavage of the thioketal linker, releasing indocyanine
green conjugated PAMAM (PAMAM-ICG). Because
of its small size, the released PAMAM-ICG penetrated
deeper into the tumor for improved photothermal and
photodynamic therapy.
Surface stealth modification during body circulation:
charge‑reversal dendrimers

PEG is an inert, non-immunogenic, and non-antigenic
polymer with excellent water solubility and biocompatibility, and PEG has been approved by FDA [71, 72].
PEGylation of dendrimers is commonly used to shield
the cationic surface of dendrimers, reduce their toxicity,
and prolong their circulation time [72, 73]. PEGylated
PAMAM dendrimers increase the systemic circulation
time by reducing the unspecific absorption and thus
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increase the accumulation in the target tissues [74].
Nevertheless, such a strategy impedes dendrimer tissue penetration and subsequent cell internalization.
PEGylated dendrimers can also enhance the solubilization of hydrophobic drugs, extend the flexibility for
dendrimer conjugation, improve DNA transfection, and
promote tumor targeting [72, 75]. However, long-term
administration of PEGylated formulations leads to the
accumulation of PEGs within tissues, leading to potential tissue toxicity and adverse effects [76–78]. In addition, increasing evidence shows that the excessive use
of PEG may lead to the production of PEG antibodies
in the body, causing accelerated blood clearance (ABC)
and shortening blood circulation time of PEGylated
materials [79–81].
Further research is thus warranted to bring these
promising nanomaterials from the bench to the bedside [72]. Acetylation of amine groups can decrease the
positive surface charges of PAMAM dendrimer and
thus reduce its toxicity. Waite et al. reported that modest acetylation (approximately 20% degree of amine was
acetylated) of PAMAM could maintain the siRNA delivery efficiency while reducing the toxicity [82]. Recently,
zwitterionic modified nanomaterials have been reported
to have a better antifouling property than PEGylated
counterparts [83]. Wang et al. reported a zwitterionic
nanocarrier self-assembled from a Janus dendrimer
[84]. The Janus dendrimer comprises two distinct dendrons: one is hydrophilic and zwitterionic end-group
functionalized, the other is modified with positively
charged arginine groups and hydrophobic moieties.
This Janus dendrimer could self-assemble into a larger
nanoparticle with zwitterionic moieties as the outer
layer. It was shown to repel proteins and gain prolonged
circulation in the blood compared to the PEGylated
nanocarriers.
Another idea is to deactivate the cationic surface
charges of dendrimers during blood circulation to minimize the nonspecific cellular uptake and adsorption
and then reactivate the positive surface charges once
inside the target tissues or cells. This is the basis for
making charge-reversal or charge-switchable dendrimers. Cues including temperature, pH, osmotic pressure, and biological signals may be utilized to reverse
charges on the dendrimer surface [85–91]. We summarize the recently reported charge-reversal chemistries
in Table 2. In general, the transformation from negative
charge to positive charge is conducive to the stability of
the materials in the blood circulation and their endocytosis, while the transformation from positive charge
to negative/neutral charge is helpful to improve the
release of nucleic acids (which will be discussed in the
following section).
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Intracellular controlled gene release

Prompt separation of nucleic acids from their carrier following cellular internalization and endosomal escape
is essential to achieving high gene transfection. It is
desirable to design a spatiotemporally controllable gene
delivery vehicle to release nucleic acids intracellularly.
The charge-reversal dendrimers are ideal candidates
(Table 2). Wang et al. reported a gene delivery system
by using the charge-reversal strategy [91]. Deoxyribonucleic acid (DNA) was electrostatically condensed by
a positively charged poly{N-[2-(acryloyloxy)ethyl]-N[p-(2,4-dinitrophenoxy)benzyl]-N,N-diethyl ammonium
chloride} (PADDAC) polymer and coated with a liposome layer to maintain the stability in blood circulation.
After cell internalization, the liposomal layer degraded
in lysosomes, resulting in the exposure of the PADDAC/
DNA complex. The over-expressed glutathione in tumor
cells triggered the charge-reversal of PADDAC moieties from positive to negative for DNA release. We
recently reported a heterogeneous dendrimer derivative (G3-acetal-NH2) having an acid-responsive charge
reversal periphery [92]. The positive surface charged
G3-acetal-NH2 has a similar pMAXGFP plasmid condensing capacity to that of native PAMAM G4. After cell
uptake, the cleavage of the acetal groups was triggered in
the weakly acidic endosome environment, and the surface of the dendrimer turned from amine-terminated to
hydroxyl-terminated. The reduction in the dendrimer
surface charge resulted in the release of the genetic payload and enhanced GFP protein expression.

Our solution: hierarchically structuring dendrimers
into dendrimer gel
Dendrimer hydrogel

When local administration is adopted, such as ocular topical instillation or intratumoral injection, issues
associated with the systemic circulation are no longer
a concern. But it is of paramount importance to retain
the formulation locally. Hydrogels, especially injectable hydrogels, benefiting from their three-dimensional network structure and adhesion property, have
been broadly served as drug depots for prolonged
drug release [93, 94]. The multifunctionality and welldefined nanostructure make dendrimer an ideal building block for producing three-dimensional cross-linked
networks, named dendrimer hydrogel (DH) [95–97].
Many chemical and physical ways were developed to
cross-link dendrimers to form hydrogels [97–103].
Recently, we developed a DH platform using the azaMichael addition cross-linking strategy and explored its
application as local drug delivery system (Fig. 3) [97].
Following the aza-Michael addition, the nucleophilic
amines on the PAMAM dendrimer surface react with
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Table 2 Surface charge-reversal chemistries
Charge Reversal

Chemistry

Negtive
⬇
Positive

Positive
⬇
Negtive

Positive
⬇
Neutral

the unsaturated ester of the terminal acrylate groups
in linear polyethylene glycol diacrylate (PEG-DA). This
dendritic-linear aza-Michael addition cross-linking
strategy is a green approach as it proceeds efficiently in
aqueous media at room temperature without the use of
a catalyst. Since the synthesis of PAMAM dendrimer is
also based on the aza-Michael addition between amine
and acrylate groups, the formed gel has similar chemical linkages to the original dendrimers. The degree of
cross-linking and gel properties can be adjusted readily
by controlling reactant concentration or amine group
density on the dendrimer surface.

Stimuli

Refs

pH

[45]

Enzyme: γ-glutamyl transpeptidase
(GGT)

[42, 85, 86]

Enzyme: Glutathione (GSH)

[91]

ROS

[90]

pH

[92]

Forming DHs expands the structural diversity of dendrimers and greatly enriches the ways of using dendrimers to deliver drugs and genes. In addition to the
delivery methods discussed above, drugs and/or genes
can be in-situ embedded in the hydrogel network. Unreacted amines on the dendrimer surface can accelerate
the ammonolysis of the ester bonds to make the hydrogel
degradable. What is more interesting is that the ammonolysis process is pH-dependent: a more acidic environment tends to slow down the ammonolysis and extend
gel degradation [104]. Importantly, cross-linking dendrimer with PEG makes the cross-linked structure more
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Fig. 3 A homogeneous dendrimer hydrogel: cross-linking strategy, tunable functionality, and application for local drug delivery system

biocompatible compared to free dendrimers in equivalent molar qualities [97, 105].
We tested this DH as a platform for intratumoral drug
delivery to treat head and neck cancer. We embedded
the anticancer drug fluorouracil in the DH and tested
its in vitro release and in vivo tumor inhibition activities
[97]. Injectable fluorouracil loaded DH formulation efficiently inhibited tumor growth following intratumoral
injection. Compared to the terminal tumor volume of the
PBS group, fluorouracil-loaded DH formulation reduced
tumor volume by four-fold following 3-week treatment.
We also designed a DH formulation to deliver the anticancer drug CPT via conjugation [47]. In this new formulation, CPT was covalently grafted to PAMAM
dendrimer. The dendrimer-CPT conjugates were then
cross-linked with PEG-DA to form DH (DH-G3-CPT).
Similarly, ammonolysis of ester bonds underlies both
CPT release and hydrogel degradation. This novel DH
drug delivery system realized a significantly prolonged
drug release over a period of 6 days in the acidic tumor
site, while a complete release of CPT from this DH at
neutral buffer only took 4 days. The sustained release
thus led to an excellent tumor inhibition effect following intratumoral injection in a mouse model of head and
neck cancer.
Glaucoma has become the leading cause of irreversible
blindness worldwide [106]. Eye drop instillation is the

most broadly used administration route to deliver drugs
to treat glaucoma [107]. DHs have been tested for topical
delivery of antiglaucoma drugs [41, 102, 108]. We developed a mildly cross-linked DH as eye drops by choosing
the antiglaucoma drug brimonidine tartrate as a model
drug [109]. This antiglaucoma drug formulation has both
flowability and adhesion due to the moderate cross-linking density. A significantly sustained brimonidine release
is also realized. This loosely three-dimensional network
of the DH formulation enables a two-phase drug release
kinetics: a burst release within the first 6 h allows the
drug to rapidly reach an effective concentration, and a
subsequent sustained release continuously supplies the
drug to maintain the therapeutic drug level for 48 h. The
corneal permeability of brimonidine by using this mildly
cross-linked DH increased by two-fold. This sustained
release and enhanced corneal permeation make the DH
formulation have great potential to improve the efficacy
of antiglaucoma drugs under topical instillation.
From dendrimer hydrogel to micro/nano gel: a more
precise way to hierarchically use dendrimers as building
blocks

DHs have shown promising structural features for
local drug delivery. We further exploited the preparation process of DH and studied whether DH on a
micro/nanoscale could be made. We combined the
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aza-Michael addition cross-linking strategy with the
inverse micro/nano-emulsion method (Fig. 4). All the
reactants are dissolved in water first and then converted into micro/nanodroplets in a continuous organic
phase in the presence of surfactants. The gelation reaction between dendrimer and PEG-DA occurs in the
micro/nanodroplets. We have successfully prepared
micro and nanogel particles with size range from several micrometers to hundreds of nanometers by changing preparation parameters [110]. The dendrimer
microgel we have prepared (3–5 μm) shows high loading of the hydrophobic drug CPT, zero-order sustained
release kinetics, and good cell internalization with
excellent cytocompatibility [110]. We modified parameters to make dendrimer nanogels and tested them for
topical delivery of antiglaucoma drugs [111]. We found
that dendrimer nanogels maximized the utility of the
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structural features of existing dendrimer and hydrogel
ocular drug delivery systems in terms of cytocompatibility, degradability, drug release kinetics, corneal permeability, and sustained IOP-lowering efficacy. The IOP
reduction treated by brimonidine tartrate-loaded nanogels was four-fold deeper than that treated by free brimonidine tartrate following 7 days of daily dosing.
Dendrimer micro/nanogels integrate the features of
dendrimer, hydrogel, and micro/nanoparticles [111].
They provide a new platform with complex functionality
for drug and gene delivery. Different formulation preparation techniques can be combined with dendrimer gelation chemistries. For instance, microfluidic technology or
flow chemistry may help produce dendrimer microgels
with uniform size as well as increase production efficiency. The adoption of the template preparation method
may be used to prepare dendrimer micro-nano gels with

Fig. 4 The combined aza-Michael addition cross-linking strategy with inverse micro/nano-emulsion technology to produce dendrimer micro/
nanogel (a) and future possible preparations to obtain dendrimer micro/nanogel by utilization of microfluidic technology or flow chemistry (b) and
template methods (c)
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better control over structure and enable the production
of hybrid materials.
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Conclusions
In this mini review article, we briefly reviewed the history of dendrimers and their features for drug and gene
delivery. Dendrimers have been widely adopted as drug/
gene delivery vehicles in various forms, including dendrimer-drug conjugates, drug/dendrimer encapsulation, dendrimer/gene complexation, and so on. We also
reviewed the challenges and solutions to dendrimerbased drug and gene delivery. In particular, we discussed
new dendritic structures reported in recent years, including size-switchable and charge-reversal dendrimers, bulk
and micro/nano dendrimer hydrogels. In summary, the
recent advances in dendrimer formulations may lead to
the generation of new drug and gene products and enable
the development of novel combination therapies.
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